

AD _____

Award Number: DAMD17-02-1-0126

TITLE: Quality of Life and Cost of Care of Prostate Cancer
Patients

PRINCIPAL INVESTIGATOR: Ravishankar Jayadevappa, Ph.D.

CONTRACTING ORGANIZATION: University of Pennsylvania
Philadelphia, Pennsylvania 19104-6205

REPORT DATE: January 2003

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20030617 067

Table of Contents

Cover.....	
SF 298.....	2
Introduction.....	3
Body.....	3
Key Research Accomplishments.....	16
Reportable Outcomes.....	17
Conclusions.....	17
References.....	
Appendices.....	18-25

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE January 2003	3. REPORT TYPE AND DATES COVERED Annual (19 Dec 01 - 18 Dec 02)	
4. TITLE AND SUBTITLE Quality of Life and Cost of Care of Prostate Cancer Patients			5. FUNDING NUMBERS DAMD17-02-1-0126	
6. AUTHOR(S) : Ravishankar Jayadevappa, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Pennsylvania Philadelphia, Pennsylvania 19104-6205 E-Mail: jravi@mail.med.upenn.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited			12b. DISTRIBUTION CODE	
13. Abstract (Maximum 200 Words) (abstract should contain no proprietary or confidential information) Due to uncertainty in the screening and treatment, debate on outcomes such as quality of and cost of care continues. The objective of this study is to assess the effects of differential treatments for prostate cancer for different ethnic groups, on quality of life and cost of care for the elderly. Another issue of interest is the comparison of efficiency and quality of care for prostate cancer offered in two distinct health care systems: Veterans Affairs (VA) and non-VA. Three specific aims of this study are: (1) to analyze and compare the quality of life and satisfaction with care of prostate cancer patients across two ethnic (African Americans and Caucasians) groups, controlling for the stage at diagnosis and co-morbidity; (2) to analyze and compare the average costs of care of prostate cancer patients across two ethnic groups, controlling for the stage at diagnosis and co-morbidity; and (3) to analyze and compare the resource utilization, treatment modalities and cost-effectiveness of prostate cancer care between VA and non-VA hospitals. During the first year of this prospective we have recruited 292 (African Americans and Caucasians) after their written consent from the Urology and radiation oncology clinics, University of Pennsylvania Health System and VA medical center.				
14. SUBJECT TERMS: quality of life, cost of care, satisfaction with care			15. NUMBER OF PAGES 28	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

INTRODUCTION

Due to uncertainty in the screening and treatment, debate on outcomes such as quality of and cost of care continues. Research has shown that the type of treatment received for a given stage of prostate cancer varies by ethnicity and age. Hence, the objective of this study is to assess the effects of differential treatments for prostate cancer for different ethnic groups, on quality of life and cost of care for the elderly. Three specific aims of this study are: (1) to analyze and compare the quality of life and satisfaction with care of prostate cancer patients across two ethnic groups, controlling for the stage at diagnosis and co-morbidity; (2) to analyze and compare the average costs of care of prostate cancer patients across two ethnic groups, controlling for the stage at diagnosis and co-morbidity; and (3) to analyze and compare the resource utilization, treatment modalities and cost-effectiveness of prostate cancer care between VA and non-VA hospitals. This study uses prospective cohort design to assess and compare, across Caucasians and African Americans, the health related quality of life (HRQOL) and cost of care for prostate cancer patients older than 65 years. A total of 280 subjects will be recruited from the urology and radiation oncology clinics at the University of Pennsylvania Health System (UPHS), and Philadelphia VA Medical Center. Baseline data will be collected within 1-2 weeks after recruitment, with subsequent follow up at three months interval for two years on demographics, clinical, HRQOL, and cost data. We will compare average cost of treatment and quality of life across two ethnic groups, controlling for stage and co-morbidity. Finally, Markov decision model will be used to analyze and compare cost-effectiveness of prostate cancer treatments across two ethnic groups and comparison will be made between VA and non-VA hospitals.

BODY

We finalized the research protocol and obtained approval from the Human Compliance and Quality, U.S. Army Medical Research and Materiel Command; the Regulatory Affairs, Institutional Review board, University of Pennsylvania; and the Research Services, VA Medical Center, Department of Veterans Affairs, Philadelphia. The process of recruiting newly diagnosed prostate cancer patients was initiated in February of 2002. The specific steps of this process are: (1) contacting the patients; (2) explaining the study; and (3) obtaining the consent.

Task 1. Recruitment of Patients

- a. Potential patients were contacted at the urology and radiation oncology clinics after introduction by their urologist and radiation oncologist. Newly diagnosed patients were also contacted at their pre- prostatectomy classes, organized by the urology clinic. The newly diagnosed prostate cancer patients were contacted at the Veteran Affairs Medical Center during their urology clinic visit.
- b. Research assistant held a detailed discussion about the study with the patients
- c. Consent was obtained from interested patients
- d. Recruitment of patients
- e. A unique patient identifier was assigned to each patient. This information will be maintained as highly confidential at all times.

Table 1 shows the monthly recruitment pattern over the past eleven months of the study period. Some newly diagnosed prostate cancer patients were at the urology clinics for a second opinion only, and were not eligible for our study. So far, we have recruited 238 newly diagnosed prostate cancer patients from the University of Pennsylvania Hospital and 54 from the Philadelphia VA Medical Center.

Table 1: Recruitment of Newly Diagnosed Prostate Cancer Patients

Month	Hospital of the University of Pennsylvania			Philadelphia VA Medical Center		
	# of eligible patients	# recruited		# of eligible patients	# recruited	
		<65	≥ 65		<65	≥ 65
February 2002	18	5	10		0	0
March 2002	10	2	5	3	1	1
April 2002	29	7	9	6	1	2
May 2002	34	5	15	7	6	1
June 2002	54	4	20	10	4	4
July 2002	40	11	20	9	2	4
August 2002	19	5	7	8	2	2
September 2002	24	5	12	12	1	7
October 2002	52	13	24	9	3	2
November 2002	40	13	22	6	2	3
December 2002	24	13	11	8	4	2
TOTAL	344	83	155	78	26	28

Task 2: Preparation of Medical Record Abstractions

A medical record abstraction form was developed to extract clinical data such as PSA scores, Gleason scores, stage of cancer at the time of diagnosis, type of treat received and diagnostic procedures performed from individual medical records (Appendix A).

Task 3: Base line Data Collection:

a. In the first eleven months of the study, we have concentrated on recruitment or newly diagnosed prostate cancer patients from the urology and radiation oncology clinics at the

University of Pennsylvania Health System (UPHS). We have also recruited patients from the Philadelphia VA Medical Center. After obtaining a written consent from the patient, we obtain his base line demographics and quality of life using the UCLA prostate cancer index and SF-36. The subsequent follow ups are to be done at three months interval for a period of two years beyond a patient's entry into the study. Data on following variables is obtained: Age, ethnicity, types of insurance, living arrangement, marital status and mortality. Clinical data collection via medical charts is currently ongoing. So far, for 44 patients, we have extracted clinical information such as: date of diagnosis, date of treatment & length of stay; type of treatment/procedures; hospital charges & reimbursements, number and type of medications; number of other procedures, principal DRG diagnostic studies and relevant medications.

b. A patient satisfaction survey was administered at the baseline and at follow-up.

Patient Follow-up and Retention

Task 4: Develop Plan for Follow-up Patient interview

a. A tracking system was developed to track patient recruitment and contact processes. During the follow-up period, three patients died, two were from the UPHS and one was from the VA. All the three prostate cancer patients died within three months of their study entry. Table 2 shows patient retention and follow-up. We provide each patient with \$10 in compensation at the time of recruitment into the study and \$5 at each successful follow-up. This has helped in generating good response rates.

Table 2: Patient follow-up and retention

	Baseline		3 month		6 month	
	# patients recruited	# of surveys completed	# eligible for follow up	# of surveys completed	# eligible for follow up	# of surveys completed
HUP	238	226	154	145	84	73
VA	54	47	25	18	20	8

Task 5: Follow up interview and Health Related Quality of Life, and Cost (resource Utilization) Data Collection

- a. Surveys were sent out at every three months to collect data from enrolled patients.
- b. Non-respondents were contacted over the telephone and were offered the option to complete the survey instruments over the telephone.
- c. Data collection and data entry was done simultaneously.
- d. Date of diagnosis, date of treatment & length of stay, other relevant medical diagnoses and medications data are being obtained from medical charts.
- e. Health Related Quality of Life data was obtained using SF-36 and UCLA Prostate Cancer Index.

Table 3: Demographics of the study group (n=156)

Variable	Percent
Race	
Caucasian	121 (77.6%)
African American	35 (22.44%)
Education	
8 grades or less	4 (2.6%)
Some high school	11 (7.1%)
High school graduate	37 (23.9%)
Some college	31 (20.0%)
College graduate	21 (13.6%)
Advanced or graduate training	50 (32.5%)
Marital status	
Married	123 (79.4%)
Single	10 (6.5%)
Widowed	6 (3.9%)
Divorced	16 (10.3%)
Current employment status	
Working full-time	81 (52.6%)
Working part-time	8 (5.2%)
Retired	53 (34.4%)
Other	10 (7.7%)
Household income	
Under \$10,000	6 (4.0%)
\$10,001 up to \$20,000	14 (9.3%)
\$20,001 up to \$30,000	15 (10.0%)
\$30,001 up to \$40,000	13 (8.7%)
\$40,001 up to \$50,000	8 (5.3%)
\$50,001 up to \$70,000	23 (15.3%)
\$75,001 or more	69 (46.0%)

The demographic characteristics of recruited patients are as shown in table 3. The mean age was 68.7 (sd.=4) years and the mean number of persons in a household was 2.4 (sd.=1.1) (please note that these are preliminary data and data input and data cleaning is currently ongoing).

Tables 3 to 5 present the demographics, general health and functional status of the newly diagnosed prostate cancer patients at the baseline for both UPHS and VA patients. Physical functioning (Table 4) is a measure of activities during a typical day and the score ranges from 10 to 30. Lower the score on physical functioning, the more limited the movements. A score on physical roles indicates problems with regular work and activities and the score ranges from 4 to 8. Lower score on this indicates more problems with regular activities. Social functioning is a measure of how physical health interferes with social activities with family, friends, neighbors or groups. A score varies from 2 to 10, 2 indicating no problem whereas 10 is a high problem. Bodily pain indicates presence of bodily pain and its impact on normal work and the score ranges from 2 to 11. A score of two mean no pain and a maximum score or eleven indicating extremely or very sever pain. Vitality measures level of energy and the score ranges from 4 to 24. Higher the score indicates better vitality. Mental health is a measure of emotional well being. The score on mental health ranges from 5 to 30. Higher the score indicates better mental health. Urinary function is a measure of urinary habits. The score varies from 5 to 19. Higher the score, better the urinary function. Bowel function indicates bowel habits and abdominal pain. The range of the score is 1 to 20. Higher a score on bowel function indicates better bowel function. Sexual function is a measure of sexual function and sexual satisfaction. The score ranges from 5 to 37, higher a score indicating better sexual functions. Similar baseline data for UPHS and VA groups is presented in Tables 4 to 6, and that by ethnicity (African American and Caucasian) is presented in Tables 9 to 11.

Table 4: Overall General Health and Prostate Cancer Index (n=156) at the baseline

Variable	Mean (standard deviation)
General Health	
Physical functioning	27.5 (4.8)
Role-physical	7.2 (1.4)
Social function	6 (1)
Bodily pain	3.3 (1.9)
Vitality	15.2 (2)
Mental health	20.7 (2.4)
UCLA Prostate Cancer Index	
Urinary function	10.5 (1.3)
Bowel function	15.9 (1.6)
Sexual function	25.3 (7.9)

Table 5: Functional Status and Prostate Cancer Index (n=156)

Variable	Percent	
General Health		
In general, would you say your health is...	Excellent	9.5%
	Very good	32.7%
	Good	26.9%
	Fair	7.7%
	Poor	3.2%
Compared to one year ago, how would you rate your health in general now?	Much better now than one year ago	29.5%
	Somewhat better now than one year ago	32.7%
	About the same as one year ago	26.9%
	Somewhat worse now than one year ago	7.7%
	Much worse now than on year ago	3.2%
UCLA Prostate Cancer Index		
Urinary bother :	No problem	69.4%
	Very small problem	14.9%
	Small problem	8.2%
	Moderate problem	4.1%
	Big problem	3.4%
Bowel bother :	No problem	0.0%
	Very small problem	0.4%
	Small problem	6.1%
	Moderate problem	15.5%
	Big problem	75.0%
Sexual bother:	No problem	49.7%
	Very small problem	9.8%
	Small problem	13.9%
	Moderate problem	13.9%
	Big problem	12.6%

Table 6: Comparison of demographics across VA and UPHS groups at the baseline (n=156)

Variable	UPHS (n=130)	VA(n=26)	
Race			
White	93.4%	6.6%	$\chi=39.3$ p= <.0001
African American	48.6%	51.4%	
Education			
8 grades or less	50.0%	50.0%	$\chi=24.4$ p=.0004
Some high school	54.4%	45.6%	
High school graduate	70.3%	29.7%	
Some college	80.7%	19.4%	
College graduate	95.2%	4.8%	
Advanced or graduate training	98.0%	2.0%	
Marital status			
Married	90.2%	9.8%	$\chi=22.0$ p=<.0001
Single	60.0%	40.0%	
Widowed	66.7%	33.3%	
Divorced	50.0%	50.0%	
Current employment status			
Working full-time	95.1%	4.9%	$\chi=22.4$ p=.0002
Working part-time	87.5%	12.5%	
Retired	64.2%	3.9%	
Other	80.0%	20.0%	
Household income			
Under \$10,000	50.0%	50.0%	$\chi=69.2$ p=<.0001
\$10,001 up to \$20,000	21.4%	78.6%	
\$20,001 up to \$30,000	66.7%	33.3%	
\$30,001 up to \$40,000	84.6%	15.4%	
\$40,001 up to \$50,000	75.0%	25.0%	
\$50,001 up to \$70,000	100.0%	0.0%	
\$75,001 or more	100.0%	0.0%	

Table 7: Comparison of overall general health and PCI of VA and UPHS groups at baseline

Variable	UPHS (n=130)	VA (n=26)	p value
Physical functioning	28.5 (sd.=3.7)	22.5(sd.=6.7)	<.0001
General Health			
Role-physical	7.4 (sd.=.2)	6.1 (sd.=1.9)	<.0001
Social function	6.1 (sd.=1.0)	5.6 (sd.=0.9)	.0650
Bodily pain	3 (sd.=1.6)	4.84 (sd.=2.5)	<.0001
Vitality	15 (sd.=2)	15.8 (sd.=1.9)	.0864
Mental health	21 (sd.=2.5)	20.9 (sd.=1.7)	.6254
UCLA Prostate Cancer Index			
Urinary function	10.6 (sd.=1.2)	9.9 (sd.=1.5)	.0130
Bowel function	15.9 (sd.=1.5)	15.4 (sd.=1.8)	.1228
Sexual function	25.8 (sd.=7.7)	22.8 (sd.=8.9)	.1287

Table 8 Comparison of functional status and PCI of VA and UPHS at the baseline

Variable	UPHS (n=130)	VA (n=26)	
General Health			
In general, would you say your health is			$\chi=33.9$ $p=<.0001$
Excellent	97.8%	2.2%	
Very Good	92.2%	7.8%	
Good	71.4%	28.6%	
Fair	58.3%	41.7%	
Poor	20.0%	80.0%	
Compared to one year ago, how would you rate your health in general now?			$\chi=3.6$ $p=.4580$
Much better now than one year ago	60.0%	40.0%	
Somewhat better now than one year ago	84.6%	15.4%	
About the same as one year ago	85.7%	14.3%	
Somewhat worse now than one year ago	81.2%	18.7%	
Much worse now than on year ago	66.7%	33.3%	
UCLA Prostate Cancer Index			
Urinary bother			$\chi=7.0$ $p=.1346$
No problem	87.3%	12.7%	
Very small problem	77.3%	22.7%	
Small problem	58.3%	41.7%	
Moderate problem	83.3%	16.7%	
Big problem	80.0%	20.0%	
Bowel bother			$\chi=6.9$ $p=.0744$
No problem	0.0%	0.0%	
Very small problem	80.0%	20.0%	
Small problem	55.6%	44.4%	
Moderate problem	73.9%	26.1%	
Big problem	86.5%	13.5%	
Sexual bother			$\chi=3.1$ $p=.5398$
No problem	84.5%	15.5%	
Very small problem	85.7%	14.3%	
Small problem	70.0%	30.0%	
Moderate problem	85.0%	15.0%	
Big problem	88.9%	11.1%	

Table 9: Comparison of demographics across ethnicity at the baseline

Variable	Caucasian (n=121)	African-American (n=35)	
Education			
8 grades or less	50.0%	50.0%	$\chi=23.0$ $p=.0008$
Some high school	36.4%	63.6%	
High school graduate	68.8%	35.2%	
Some college	80.7%	19.3%	
College graduate	85.7%	14.3%	
Advanced or graduate training	92.0%	8.0%	
Marital status			
Married	84.6%	15.4%	$\chi=21.0$ $p=.0001$
Single	70.0%	30.0%	
Widowed	50.0%	50.0%	
Divorced	37.5%	62.5%	
Current employment status			
Working full-time	88.9%	11.1%	$\chi=18.5$ $p=.0010$
Working part-time	75.0%	25.0%	
Retired	66.0%	34.0%	
Other	40.0%	60.0%	
Household income			
Under \$10,000	50.0%	50.0%	$\chi=48.3$ $p<.0001$
\$10,001 up to \$20,000	21.4%	78.6%	
\$20,001 up to \$30,000	53.3%	46.7%	
\$30,001 up to \$40,000	84.6%	15.4%	
\$40,001 up to \$50,000	75.0%	25.0%	
\$50,001 up to \$70,000	82.6%	17.4%	
\$75,001 or more	95.7%	17.4%	

Table 10: Comparison of mean scores of general health and PCI across ethnicity at the base line

Variable	Caucasian (n=121)	African American (n=35)	p value
General Health			
Physical functioning	28.3 (sd.=4.4)	24.8 (sd.=5.6)	.0005
Role-physical	7.4 (sd.=1.2)	6.5 (sd.=1.8)	.0017
Social function	6.1 (sd.=1.1)	5.6 (sd.=.79)	.0232
Bodily pain	3.0 (Sd.=1.7)	4.3 (sd.=1.9)	.0003
Vitality	14.9 (sd.=1.9)	16.2 (sd.=2.2)	.0024
Mental health	20.7 (sd.=2.6)	20.7 (sd.=1.8)	.9381
UCLA Prostate Cancer Index			
Urinary function	10.6 (sd.=1.3)	10.4 (sd.=1.2)	.6422
Bowel function	25.9 (sd.=1.6)	15.9 (sd.=1.5)	.8526
Sexual function	25.6 (sd.=8)	24.3(sd.=7.2)	.4156

Table 11: Comparison of functional status and PCI across ethnicity at the baseline

Variable	Caucasian (n=121)	African American (n=35)	
General Health			
In general, would you say your health is			$\chi=29.9$ $p<.0001$
Excellent	89.1%	10.9%	
Very Good	90.2%	9.8%	
Good	59.5%	40.5%	
Fair	41.7%	58.3%	
Poor	80.0%	20.0%	
Compared to one year ago, how would you rate your health in general now?			$\chi=5.2$ $p=.2601$
Much better now than one year ago	40.0%	60.0%	
Somewhat better now than one year ago	69.2%	30.8%	
About the same as one year ago	80.6%	19.4%	
Somewhat worse now than one year ago	75.0%	25.0%	
Much worse now than on year ago	89.3%	16.7%	
UCLA Prostate Cancer Index			
Urinary bother			$\chi=5.3$ $p=.2580$
No problem	80.4%	19.6%	
Very small problem	63.6%	36.4%	
Small problem	66.7%	33.3%	
Moderate problem	83.3%	11.7%	
Big problem	100.0%	0.0%	
Bowel bother			$\chi=6.3$ $p=.0991$
No problem	0.0%	0.0%	
Very small problem	100%	0.0%	
Small problem	55.6%	44.4%	
Moderate problem	65.2%	34.8%	
Big problem	80.2%	19.8%	
Sexual bother			$\chi=5.7$ $p=.2218$
No problem	84.5%	15.5%	
Very small problem	64.3%	35.7%	
Small problem	65.0%	35.0%	
Moderate problem	75.0%	25.0%	
Big problem	83.3%	16.7%	

Task 7: Indirect Cost Data Abstraction Design (Appendix b)

A survey to obtain indirect cost data was developed and sent out to all recruited patients at post diagnosis follow up period.

Task 8: Abstraction of Medical Records

- a. Medical record abstractions is currently being performed and will continue during the follow-up period.
- b. Data entry and quality control measures are ongoing.
- c. Follow-up interviews and data collection are being done at every three months.

Task 9: Data entry and coding

- a. Data dictionary was created
- b. Database was set up in Microsoft Access
- c. All the data obtained is being coded (ongoing).
- d. All the data is being entered (ongoing).
- e. As of today our database consist of baseline QOL data on 156 patients.

KEY RESEARCH ACCOMPLISHMENTS

During the past eleven months we have established the recruitment and follow up program. We have successfully recruited total of 292 newly diagnosed prostate cancer patients from the urology clinic, radiation oncology clinic and VA medical center. Patient recruitment, data collection on Quality of Life, Satisfaction with Care, Direct and indirect medical cost at baseline and follow-up is currently ongoing. Upon recruitment each patient is offered \$10 in compensation and each follow-up \$5 is offered upon completion of surveys. We have found this to be helpful in generating good response rates. Also, another important observation is that involvement of urologist has greatly enhanced the recruitment and retention of patients.

REPORTABLE OUTCOMES

1. Presented an abstract at the Gerontological society of America (Appendix C)
Jayadevappa R, Chhatre S, Boyle J, Kvam K, Bloom BS, Malkowicz. Variations in Cost of Prostate Cancer Across Age and Ethnicity. The Gerontologist. 55th Annual Scientific Meeting "Relationships in a Changing World: From Aging Cells to Aging Societies", Volume 42, 1, October 2002.
2. Under review- a long term study on cost effectiveness of prostate cancer treatment and disease progression entitled "Cost Effectiveness of Prostate Cancer Treatment Across Age and Ethnicity" Applied to: The American Cancer Society - Research Scholar Grant.
Study start date: 07/01/2003 End Date: 06/30/2007
Principal Investigator: Ravishankar Jayadevappa, Ph.D.
3. Jayadevappa R, Malkowicz B, Weinder M, Chhatre S, Bloom BS. Direct Medical Care Cost of Patients with Prostate Cancer Across Age and Ethnicity. (working paper)
(brief description of the article is shown in Appendix D)
4. Under review- a Collaborative Center grant entitled "Quality of Life in Long Term Survivors of Prostate Cancer" the Abramson Cancer Center, Collaborative Pilot project Program.
Start Date: 06/01/2003 End Date 05/31/2003
Principal Investigator: Ravishankar Jayadevappa, Ph.D.

CONCLUSIONS

Most of the proposed targeted activities were achieved in the year. We have a well-established recruitment and retention mechanism in place. The support of Urologist has been very helpful toward this. As of now, we have recruited 292 newly diagnosed prostate cancer patients. We will aim to achieve our goal of recruiting equal number of African Americans in the coming month. The process of data entry and data quality control is established and is ongoing. In addition, we have been able to publish and present the preliminary information. We have also used this as a foundation for developing two proposals on prostate cancer to the American Cancer Society and Cancer Center Collaborative Program.

Appendix A
PROSTATE CANCER PROJECT
MEDICAL RECORDS ABSTRACTION SHEET

Date of Record Abstraction ----/----/----

- (1) Medical Record # _____
- (2) Patient unique ID # _____
- (3) Date of Birth ___/___/___
- (4) Marital status: 1= married 2 = single 3 = widowed 4 = divorced
- (5) Ethnicity: 1 = African American 2 = White 3 = Hispanic 4 = other -----
- (6) Mortality (Last progress note) Yes _____ No _____
- (7) Pre-hospital living arrangement
- 1 = Nursing home 2 = Care facility other than nursing home
- 3 = In Community with wife/husband and/or care giver
- 4 = Lives alone 5 = Don't know
- (8) Health Insurance
- 1 = Medicaid Yes No 2 = Medicare Yes No
- 3 = Managed Care Yes No 4 = Private Yes No
- 5 = None
- (9) Date of First Prostate Cancer Diagnosis ___/___/___
- (10) PSA Score Before _____ After _____ (11) TNM Stage _____
- (12) Indicate histological score on Gleason (2-10) _____
- (13) Are pelvic lymph nodes involved? 1 = Yes 2 = No 9 = unknown
- (14) Stage this patient on the MD Anderson Staging
- Staging Classification (use highest grade listed) A _____ B _____
- (A) 1 = Group I (B) 1 = well diff.
- 2 = Group II 2 = Mod. Diff.
- 3 = Group III 3 = Poorly diff.
- 4 = Group IV

- (15) Stage this patient on the American Urological Staging scale _____
 1 = Stage A1 Focal 2 = Stage A2 Diffuse
 3 = Stage B1 confined to prostate, small Discrete nodule
 4 = Stage B2 confined to prostate, nodule > 1.5 or multiple nodules
 5 = stage C1 tumor 70g or less, locally advanced disease; no involvement of seminal vesicles
 6 = stage C2 tumor >70g; involvement of seminal vesicles
 7 = stage D1 pelvic lymph node metastases or urethral obstruction causing hydronephrosis
 8 = stage D2 Bone or distant lymph node or organ or soft tissue metastases

- (16) Change in PSA score and Stage: 1 = Yes 2 = No 9 = unknown

If Yes, What is the current PSA score: _____

PSA Score and stage at subsequent diagnosis: _____ and _____

PSA score and Stage at 3 months (after diagnosis): _____ and _____

PSA score and Stage at 6 months (after diagnosis): _____ and _____

PSA score and Stage at 9 months (after diagnosis): _____ and _____

PSA score and Stage at 12 months (after diagnosis) _____ and _____

PSA score and Stage at 15 months (after diagnosis) _____ and _____

PSA score and Stage at 18 months (after diagnosis) _____ and _____

PSA score and Stage at 21 months (after diagnosis) _____ and _____

PSA score and Stage at 24 months (after diagnosis) _____ and _____

PROCEDURES (TYPE OF TREATMENT)

- (17) Radiation Tx -Type 1=Yes 2 = No *If yes, specify*

1 = external beam 2 = interstitial 3 = extended field

- (18) Amount of RADS _____

- (19) Surgery: 1=Yes 2 = No *If yes, specify*

1 = Pelvic LN dissection 2 = TURP

3 = Orchiectomy 4 = Radical Prostatectomy

- (20) Hormone therapy: 1=Yes 2 = No *If yes, specify* _____

- (21) Watchful waiting 1=Yes 2 = No *If yes, specify* _____

- (22) Other procedures or treatments: 1=Yes 2 = No

If yes, specify _____

DIAGNOSTIC STUDIES

(23) Bone scan: 1=Yes 2 = No

If yes, 1 = + for bone mets 2 = neg 3 = not done

(24) CT Scan of Pelvis: 1=Yes 2 = No

If yes, 1 =+ for lymph node mets 2 = neg 3 = not done
4 = Local invasion to seminal vesicle(s) or bladder 5 = other

(25) Relevant Medical Diagnosis: Yes No *If yes check all that apply:*

- 1 = Depression 2 = Stroke 3 = Parkinsonism 4 = Dementia
- 5 = UTI 6 = Urethritis 7 = Asthama 8 = Arthritis of knees or hips
- 9 = Diabetes mellitus 9 = CHF/MI heart troubles angina
- 0 = COPD 11 = Cancer 12 = Other (e.g., M.S., neurological)

Other(s) _____

(26) Relevant medications at the time of review: Yes No *If yes check all that apply*

List all the Prescribed Medications (at baseline):

List all the Prescribed Medications (After):

Appendix B
INDIRECT COST

Please complete the following section related to your expenses that are not covered by your health insurance (Note: please use only expenses that are attributable to prostate cancer).

I Direct non Medical Cost:

1. During the last three months have you incurred any out of pocket expenses on prescribed and non-prescribed medication (s)? 1=Yes 2 = No

If yes,

(A) Monthly average expenses on prescribed medications _____

(B) Monthly average expenses on non-prescribed medication (includes any over the counter and pain medications) _____

2. Monthly average parking expenses during your inpatient and outpatient visit (s) in the last three months _____

3. Monthly average transportation expenses during inpatient and outpatient visit(s) cost in the last three months _____

4. Monthly average expenses of meals outside home that are directly attributable to your prostate cancer during the last three months _____

5. Monthly expenses associated with care giver (s) (includes: spouse, children, or other) during the last three months _____

6. Other out of pocket expenses that are not specified above (please specify the amount and type) _____

II. Patient and care giver(s) time

Do you take more time now to do the following activities?

(1) Traveling 1=Yes 2 = No

If yes, total additional time needed for all of your daily and leisure traveling activities _____

(2) Did you miss work or have decreased your work hours? 1=Yes 2 = No

If yes, total number of days of work missed in the last three months _____

total number of decreased work hours in the last three months _____

(3) Do you now take more time to do the usual house work? 1=Yes 2 = No

If yes, additional time needed _____

(4) Do you now need more help from your care givers (spouse, children or others)

1=Yes 2 = No

If yes, additional time provided by your care giver(s) everyday _____

Appendix C

THE GERONTOLOGIST


IN THIS ISSUE:

PROGRAM ABSTRACTS

55th Annual Scientific Meeting

**"Relationships in a Changing World:
From Aging Cells to Aging Societies"**

VOLUME 42
SPECIAL ISSUE I
OCTOBER 2002



provides a framework for future phases of the project and has laid important groundwork for in-depth research in understanding communities in general from a multitude of perspectives.

UNDERSTANDING WHY AFRICAN AMERICANS PARTICIPATE IN RESEARCH

T. Perkins, M. Perkinson, Washington University School of Medicine, St. Louis, MO.

Recruiting African Americans for research presents special challenges for investigators. This study addresses African Americans' attitudes toward participation in health-related research. Ten community leaders and researchers who had professional experience working with African Americans were interviewed regarding recruitment barriers and research benefits for the older African American population. In addition, thirty-seven African American spousal caregivers of frail, older husbands were interviewed regarding their participation in a caregiving study. Primary reasons for participation in health-related research included the desire to obtain information on caregiving and health issues, help others, and talk to someone. A better understanding of the reasons African Americans participate in health-related research projects and the aspects of participation they find most satisfying is an essential step toward developing more effective recruitment strategies for this population.

VARIATIONS IN COST OF PROSTATE CANCER ACROSS AGE AND ETHNICITY

R. Jayadevappa, S. Chhatre, J. Boyle, K. Kvam, B. Bloom, B. Malkowicz, University of Pennsylvania, Philadelphia, PA.

Objective: To determine variations in treatment type and direct cost of prostate cancer across two ethnic and age groups (< 65 and ≥ 65). Methods: Retrospective Cohort Control Design. We randomly selected 120 prostate cancer patients (sixty African Americans and sixty Caucasians), treated between 1997-2001 in an academic medical center. Control group consisted of 240 patients without prostate cancer, matched by ethnicity, age, and Charlson comorbidity score. Results: Average incremental cost of prostate cancer was \$2,532 for African Americans and \$3,682 for Caucasians. Average incremental cost of prostate cancer treatment for elderly was 7% higher than younger patients. Average cost of prostate cancer treatment for elderly African Americans was 50% higher than younger patients, whereas for Caucasians, this was 32% lower. Charlson's Comorbidity scores were more than 2-fold greater for African Americans than Caucasians (4.5 vs 2). 58% of African Americans received radiation compared to 42% of Caucasians; 51% of African Americans and 67% of Caucasians received surgery; 47% of African Americans received hormone therapy compared to 34% of Caucasians. Results indicate that ethnicity, age, comorbidity and disease stage importantly affect cost of care and type of treatment received by prostate cancer patients.

PSYCHOMETRIC EVALUATION OF THE GERIATRIC DEPRESSION SCALE USING AN ASIAN AMERICAN ELDERLY SAMPLE

A. Mui, S. Kang, L. Chen, Columbia University, New York, NY.

This study is based on a regionally representative sample of 407 Asian American elders who belong to one of the following six ethnic groups: Chinese, Korean, Indian, Filipino, Vietnamese, or Japanese. The interviews were conducted in English, Chinese, Korean, Hindi, Tagalog and Vietnamese. In order to evaluate the cross-cultural utility of the Geriatric Depression Scale (GDS), the present study examined its psychometric properties. The analyses on the whole Asian elderly sample indicated that the Cronbach's alpha coefficient of the GDS was .90 and the split-half reliability coefficient was .80. The Cronbach's alpha coefficients of the GDS for the six Asian subgroups ranged from .85 to .92 and the split-half reliability coefficients ranged from .76 to .86. The data suggested that the GDS has good internal consistency and acceptable reliability for use among the Asian American elderly population.

97

SUCCESSFUL AGING

LIVING PAST A HUNDRED

D. Marchese, Films for the Humanities & Sciences, Princeton, NJ.

One (57 minutes, color) videotape/1999 Over the course of the 20th century, the life span in the West has doubled. What will be the impact of increasing longevity on society, the environment, and the global economy? Combining commentary from leading scientists with case studies of centenarians from the U.S. and around the world, this documentary examines elements that influence life expectancy—diet, fitness, physical and mental health, sexuality, and even plastic surgery—and considers the long-term implications of increased longevity.

LEARNING TO FLY: THE WINGS OF POSSIBILITY

L. Kussmann, Aquarius Productions, Sherborn, MA. The acclaimed author of *Fire in the Belly* presents an exhilarating look at the flying trapeze and at the potential offers for growth and transformation. Learning to Fly teaches us to soar on the wings of possibility. As we watch Sam Keen and fellow student progress through breathtaking exercises, Keen imparts moving revelations about risk taking, trust, bravado, true strength, falling and letting go. 1999 Part 3: AGELEARN Run Time: 1999, 28 minutes, Price: \$90. Recipient, Best of the Silver Images Film Festival 2002, Documentary What the Media is Saying... "Sam Keen is one of our liveliest minds. It's a joy to go with him as a guide by the byways of the soul in search for greater meaning in life." -Daniel Goleman, Author of *Emotional Intelligence*

Appendix D

Direct Medical Care Cost of Patients with Prostate Cancer Across Age and Ethnicity

(a) Introduction and Objective: Prostate cancer (PC) is the leading cancer among men in the US and a major health problem in the elderly. Cost and utility of health status is relevant to many health conditions, the multiple treatment options for PC provide a unique arena for examining the costs and resource utilization of care. Objective of the paper was to analyze cost and resource utilization of PC patients by age and ethnicity.

(b) Methods: This was a retrospective cohort control study. Sample consisted of 120 randomly selected African Americans and Caucasians, 40 years, diagnosed and treated for prostate cancer between 1997-2000 at an urban academic hospital with at least two years of enrollment in the health system. The controls were 240 patients from the same database, matched by age, ethnicity and Charlson co-morbidity score (CHS). Demographic, clinical and direct cost data was obtained from medical chart review and the Pennsylvania Integrated Clinical and Research Database. Costs were defined as actual charges for specific services, we used an average cost to charge ratio of .80. Costs attributed to prostate cancer were identified using ICD and CPT codes. Demographics and clinical variables were compared using t-test and chi-square. Total, incremental and prostate cancer costs per patient over three years was compared between groups. Log linear regression models were used to analyze the factors associated with total cost.

Table 12 : Characteristics of Prostate cancer patients

Variables	African American (n=60)	Caucasians (n=60)
Mean age (years)	72.63 (sd=12)	69 (9.5)
Charlson score	4.5 (sd=3.35)	2 (sd=2.4)
Marital status		
Married	37 (61.7%)	47 (79.70%)
Single	10 (16.7%)	8(13.60%)
Widowed	8 (13.30%)	1 (1.70%)
Divorced	4 (6.70%)	2 (3.40%)
Health Insurance		
Medicare	3 (6%)	5 (8%)
Managed care	16(27%)	32(54%)
Private	2(3%)	1(1%)
Medicare-Managed care	38((64%)	20(34%)
Medicare-Medicaid		1 (1%)
Deceased	14 (23%)	7 (12%)

(c) Results: As shown in table 12, the mean age of African American prostate cancer patient was 73 yrs, and mean Charlson co-morbidity score was 4.5. For Caucasians, it was 69 yrs and 2 respectively. The difference in Charlson co-morbidity score was statistically significant. Marital and health insurance status was comparable. African Americans had higher PSA at diagnosis (19.4) than Caucasians (13.6). Mean Gleason scores (6.7) were comparable across two ethnic groups. Treatments for prostate cancer varied by age and ethnicity (table 3). Log regression of total sample showed that prostate cancer patients had 57% higher total direct medical cost. While Charlson Co-morbidity score was positively associated with cost, age and ethnicity were not. Log linear regression model for the prostate cancer group showed ethnicity and Charlson co-morbidity were associated with cost.

Table 13: Disease characteristics of patients

Variables	African American (n=60)	Caucasians (n=60)
PSA score (at the time of diagnosis)	19.4 (sd=28.5)	13.6 (sd=20.2)
PSA score (post treatment)	3.1 (sd=10.3)	.94 (sd=1.6)
Gleason score (average)	6.7 (sd=1.66)	6.5 (sd=1.21)
Lymph node involved-yes	5 (8.3%)	2 (3.4%)

Table 14: Treatment and cost of prostate cancer

	African American (n=60)		Caucasians (n=60)	
	< 65 yr	65 yr	< 65 yr	65 yr
Radiation (%)	17	67	24	53
Surgery (%)	75	47	91	58
Hormone therapy(%)	31	51	19	47
Mean total cost of PC patients (\$)	19,628	19,710	18,038	22,511
Mean PC cost (\$)	5,731	4,833	7,907	6,727
Mean incremental cost(\$)	1,134	1,126	11,529	5,165

d) Conclusions: African American prostate cancer patients have higher co-morbidity and lower incremental cost. Charlson co-morbidity, age, and ethnicity are important factors associated with the cost of care and type of treatment received.